ORIC selects 400 mg rinzimetostat dose for Phase 3 after 93% rPFS; $420M runway
ORIC selected 400 mg once daily rinzimetostat dose for its Himalayas-1 Phase 3 trial in post-abiraterone mCRPC after data showing landmark rPFS rates of 93%, 84% and 84% at 3-5 months, with only one Grade 3 adverse event. Cash, equivalents and investments were $419.7 million, funding operations into 2H 2028.
1. Phase 3 Dose Selection and Efficacy Data
ORIC selected rinzimetostat 400 mg once daily for its Himalayas-1 global Phase 3 registrational trial in post-abiraterone mCRPC, based on dose optimization data showing landmark rPFS rates of 93%, 84% and 84% at 3, 4 and 5 months, respectively. Safety profile was highly differentiated, with only one Grade 3 treatment-related adverse event and no Grade 4 or 5 events.
2. Early mCRPC Data Reinforces Durability
In patients previously treated with androgen receptor inhibitors, the 400 mg daily dose achieved landmark rPFS rates of 93%, 85% and 85% at 3, 4 and 5 months, respectively, supporting its potential to sustain benefits from AR inhibition and outperform existing therapies like Zytiga®, which has a median rPFS of 3.4 months.
3. Enozertinib Trial Progress and Upcoming Milestones
Enrollment is complete for the Phase 1b monotherapy trial in EGFR exon 20 insertion advanced NSCLC and continues in atypical EGFR mutation cohorts and combination with subcutaneous amivantamab. ORIC expects first-line EGFR atypical monotherapy and exon 20 insertion monotherapy and combination data in the second half of 2026.
4. Strong Cash Position Funds Through 2H 2028
As of March 31, 2026, ORIC held $419.7 million in cash, cash equivalents and investments, including $59.9 million net proceeds from its at-the-market program, providing financial runway into the second half of 2028 to support multiple late-stage oncology programs.